C5 Antibody (029-03): sc-58934
- C5 Antibody (029-03) is a mouse monoclonal IgG1 provided at 100 µg/ml
- raised against full length native C5 of human origin
- recommended for detection of C5 in normal human plasma (PEG precipitated C5) in non reduced form only of human origin by WB and ELISA; non cross-reactive with plasma from C5 deficient patients
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for C5 Antibody (029-03). This work is in progress.
QUICK LINKS
C5 Antibody (029-03) is a mouse monoclonal IgG1 antibody that detects C5 in human samples through applications such as western blotting (WB) and enzyme-linked immunosorbent assay (ELISA). C5 is a crucial component of the complement system, playing a pivotal role in immune response by being cleaved into C5a and C5b during complement activation. C5a acts as a potent anaphylatoxin, which is essential for mediating inflammatory responses and recruiting immune cells to sites of infection or injury. This process is vital for the elimination of pathogens and the initiation of tissue repair. C5a exerts its effects by binding to specific G protein-coupled receptors on myeloid leukocytes, leading to a cascade of proinflammatory events, including cellular degranulation and cytokine release. Proper functioning of C5 and its derivatives is critical, as dysregulation can contribute to various pathophysiological conditions, including asthma and bacterial meningitis. Anti-C5 antibody (029-03) is an invaluable tool for researchers studying the complement system and its implications in immune responses and related diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
C5 Antibody (029-03) References:
- Deficiency of complement component 5 ameliorates glaucoma in DBA/2J mice. | Howell, GR., et al. 2013. J Neuroinflammation. 10: 76. PMID: 23806181
- Genetic variants in C5 and poor response to eculizumab. | Nishimura, J., et al. 2014. N Engl J Med. 370: 632-9. PMID: 24521109
- Complement Component 5 Mediates Development of Fibrosis, via Activation of Stellate Cells, in 2 Mouse Models of Chronic Pancreatitis. | Sendler, M., et al. 2015. Gastroenterology. 149: 765-76.e10. PMID: 26001927
- Complement component 5 promotes lethal thrombosis. | Mizuno, T., et al. 2017. Sci Rep. 7: 42714. PMID: 28205538
- Magnetic bead based assays for complement component C5. | DiScipio, RG. and Schraufstatter, IU. 2017. J Immunol Methods. 450: 50-57. PMID: 28757372
- The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. | Röth, A., et al. 2020. Blood. 135: 912-920. PMID: 31978221
- The case for complement component 5 as a target in neurodegenerative disease. | Stennett, A., et al. 2023. Expert Opin Ther Targets. 27: 97-109. PMID: 36786123
- Hepatic glucuronyl C5-epimerase combats obesity by stabilising GDF15. | He, F., et al. 2023. J Hepatol. 79: 605-617. PMID: 37217020
- Complement Component 5 (C5) Deficiency Improves Cognitive Outcome After Traumatic Brain Injury and Enhances Treatment Effects of Complement Inhibitors C1-Inh and CR2-Crry in a Mouse Model. | Chen, M., et al. 2023. Neurotrauma Rep. 4: 663-681. PMID: 37908321
- Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration. | Jindal, S., et al. 2024. Mol Immunol. 165: 29-41. PMID: 38142486
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
C5 Antibody (029-03) | sc-58934 | 100 µg/ml | $322.00 |